The Filing Desk

MaxCyte vs Alpha Teknova

MaxCyte MXCT · Alpha Teknova TKNO · Life Sciences Tools & Services

Alpha Teknova reported revenue of $40 million in fiscal 2025, 1.2 times MaxCyte's $33 million in fiscal 2025. MaxCyte's revenue fell 14.5% in its latest year, and Alpha Teknova's grew 7.3%. MaxCyte had an operating margin of -157.1%, against -41.9% at Alpha Teknova. Free cash flow was −$36 million at MaxCyte and −$10 million at Alpha Teknova.

Side by side

MaxCyteAlpha Teknova
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$33M$40M
Revenue growth−14.5%7.3%
Revenue growth a year, last 5 years4.7%5.3%
Gross margin81.2%33.2%
Operating margin−157.1%−41.9%
Net margin−135.1%−42.6%
Free cash flow−$36M−$10M
Free cash flow margin−109.5%−24.2%
Return on capital—−22.0%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.5%14.4%
Last close$1.28$7.81
P/E at the last close——
Insider trades, last 12 monthsbought $120,780, sold $8,316bought $143,500, sold $0
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MaxCyteAlpha Teknova
Operating margin
Percent of revenue
MaxCyteAlpha Teknova
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MaxCyteAlpha Teknova

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MaxCyte and Alpha Teknova pages.